DNA Transcription & Translation: Gene Expression Explained

Gene regulation controls whether genes are expressed or not, occurring primarily at the transcriptional level where regulatory proteins bind to DNA sequences to either activate or repress gene expression; in prokaryotes like E. coli, this is achieved through operons such as the lac operon (positive control where lactose binding removes repression) and trp operon (negative control where tryptophan binding maintains repression), while eukaryotes use transcription factors that act as activators or repressors to regulate gene expression.

Gene expression is controlled at multiple levels in eukaryotes (epigenetic control through DNA methylation and histone acetylation, transcriptional control via enhancers and transcription factors, post-transcriptional control through alternative splicing and RNA interference, translational control via eIF2-GTP interactions, and post-translational control through phosphorylation and ubiquitination), while prokaryotes primarily regulate gene expression at the transcriptional level through operons, such as the repressible trp operon (which stops tryptophan synthesis when tryptophan is abundant) and the inducible lac operon (which activates lactose metabolism only when lactose is present and glucose is low).

Gene regulation is the process by which cells control which genes are expressed and at what levels, enabling different cell types to develop specialized functions despite containing identical DNA; prokaryotes use operons (clusters of genes regulated by a single promoter) for efficient gene control, while eukaryotes employ more complex mechanisms including chromatin structure (euchromatin vs heterochromatin), epigenetic modifications (histone modifications and DNA methylation), transcription factors, and post-transcriptional regulation (alternative splicing and non-coding RNAs like miRNAs); these regulatory mechanisms are fundamental to embryonic development, where maternal effect genes establish body plans through morphogen gradients, and are disrupted in diseases like cancer through mutations in oncogenes and tumor suppressor genes.

In eukaryotic gene regulation, promoters are DNA sequences where RNA polymerase binds to initiate transcription, while transcription factors are proteins that bind to specific DNA sequences to regulate gene expression; enhancers are regulatory DNA elements that can increase transcription rates when bound by activator proteins, and these components work together with the transcription initiation complex to control when and how much a gene is expressed.

Gene regulation involves promoters (upstream DNA sequences where RNA polymerase and transcription factors bind, containing AT-rich TATA box), enhancers (DNA regions increasing transcription, bound by activator proteins, can be far from genes), and silencers (decrease transcription, bound by repressor proteins). Epigenetic regulation includes DNA methylation (adding methyl groups to CpG islands, generally repressing transcription) and histone modifications. Histone acetylation relaxes DNA coiling and increases transcription, while deacetylation tightens coiling and decreases transcription. These mechanisms control gene expression without changing DNA sequence.

Point mutations include silent (no amino acid change), missense (one amino acid substitution), and nonsense (premature stop codon). Frameshift mutations always alter amino acid sequences by shifting the reading frame. Protein functionality depends on mutation type: silent mutations preserve function; nonsense mutations produce truncated non-functional proteins; missense mutations may preserve function if amino acids are chemically similar (conservative) or disrupt it if very different (non-conservative).

A mutation is a change in DNA sequence that always changes mRNA codons and usually affects protein structure and function. Point mutations (substitutions) include: silent (no amino acid change), missense (one amino acid change), and nonsense (creates stop codon). Conservative missense changes similar amino acids with minimal impact; non-conservative changes chemically different amino acids with larger effects. Frameshift mutations (insertions/deletions) change all codons after the mutation, causing large structural changes and usually non-functional proteins. The general principle is that more changes to amino acid sequence lead to more changes to protein structure and function.

Genetic mutations are classified into four main types based on their effects on protein structure: (1) Nonsense mutations create premature stop codons (UAA, UAG, UGA in mRNA), resulting in truncated proteins with fewer amino acids; (2) Missense mutations substitute one nucleotide for another, changing a single amino acid in the protein sequence, with severity depending on the amino acid characteristics and position; (3) Silent mutations substitute nucleotides but result in the same amino acid due to codon degeneracy; (4) Frameshift mutations (insertions or deletions of nucleotides not in multiples of three) completely alter the reading frame, changing all subsequent codons and typically producing non-functional proteins. Mutations in non-coding regions like promoters or introns generally do not affect protein structure unless they disrupt splice sites.

To determine mutation effects: (1) Transcribe DNA to mRNA using complementary base pairing (A-U, G-C), (2) Find the start codon (AUG) to establish the reading frame, (3) Translate codons to amino acids using the genetic code. Silent mutations (same amino acid) have no effect; missense mutations (different amino acid) may have variable effects; nonsense mutations (early stop codon) are usually lethal; frameshift mutations (reading frame change) completely alter the protein from the mutation point.

Gene mutations are classified by their effects on protein synthesis: silent mutations change codons but code for the same amino acid due to genetic code redundancy; missense mutations change one amino acid; nonsense mutations create premature stop codons, truncating proteins. Frameshift mutations change the reading frame, affecting all subsequent codons and typically causing more severe effects. Deletion of a single nucleotide is more damaging than deletion of a complete codon.

Insulin production exemplifies biotechnology's medical applications: insulin-producing genes are extracted from animals and introduced into host cells that reproduce sexually, creating multiple copies for treating diabetes. Modern biotechnology applications include vaccine production, PCR (polymerase chain reaction), and DNA fingerprinting for criminal investigations. Golden rice demonstrates nutritional enhancement through introducing vitamin A-producing genes from carrots into rice. The first recombinant DNA was constructed in 1972 by Stanley Cohen and Herbert Boyer using salmonella bacteria. Plasmids serve as vectors - double-stranded, circular DNA molecules that exist independently of bacterial chromosomes and can self-replicate. The gene cloning process involves: constructing recombinant DNA by attaching desired genes to plasmids, introducing into host cells, allowing host cells to divide, and the plasmid replicating along with host DNA to create multiple cells each containing the desired gene.

Modern biotechnology is revolutionizing medicine through mRNA vaccine technology, which earned its discoverers the Nobel Prize for its potential against infectious diseases and cancers. CRISPR-Cas9 gene editing enables precise genetic modifications, already demonstrating life-saving applications for conditions like spinal muscular atrophy. These advances represent paradigm shifts in treating previously untreatable conditions, though accessibility and cost remain significant barriers to universal benefit.

CRISPR is a revolutionary gene editing technology using guide RNA to direct Cas9 enzyme to specific DNA locations for precise cuts and modifications. This enables treatment of genetic diseases and research applications. Modern insulin production uses recombinant DNA: the human insulin gene is inserted into bacterial cells grown in bioreactors, producing human insulin at scale. This replaced expensive, limited animal-derived insulin, making treatment accessible worldwide.

The instructor explains biotechnology applications: insulin is a peptide hormone with A chain (21 amino acids) and B chain (30 amino acids) connected by disulfide bonds. Proinsulin is the precursor containing C peptide, which is cleaved during maturation. Recombinant DNA technology involves: isolation of DNA, cutting with restriction enzymes, ligation into vectors, transformation into host cells, and expression of recombinant proteins. Human insulin is produced using this technology. Bioreactors (stirred tank and airlift types) enable large-scale production. Downstream processing involves purification and recovery of biological products.

The first synthetic human insulin was produced in 1978 using genetically modified Escherichia coli bacteria. This breakthrough was only possible after Frederick Sanger determined the exact amino acid sequence of insulin (earning one of his two Nobel Prizes) and after scientists learned to manipulate DNA through recombinant DNA technology. From 1980 onward, recombinant insulin was produced on a large scale, with Humulin becoming one of the most widely used brands.